Mutational profile of KRAS-positive colorectal cancer
Open Access
- 3 March 2022
- journal article
- research article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 47-56
Abstract
Aim: to study the features of the molecular genetic profile of KRAS-positive colorectal cancer (CRC).Material and Methods. The study included 42 patients diagnosed with colorectal cancer. The KRAS gene mutation was detected in tumor tissue of these patients by real-time PC R. Using the next generation sequencing technology (NGS ) on the Illumina platform, the genes involved in the molecular pathogenesis of colorectal cancer, namely KRAS, BRAF, NRAS, APC, TP53, SMAD2, SMAD4, FBXW7, PIK3CA, CTNNB1, TCF7L2, MLH1, MSH2, MSH3, MSH6, ATM, TGF-BR2, AKT1, CDC27, CASP8, MAP2K4, DCC, DMD, MAP7, ERBB2, P3H3, MIER3, CADM1, FLT4, PTPN12, PIK3R1, and EP300 were analyzed. Sample preparation of libraries from isolated DNA was carried out using commercial kits GeneRead DNAS eq Targeted Panel v2 Human Colorectal Cancer (Qiagen, USA ); NEBNext Ultra DNA library Prep kit for Illumina and NEBNext Multiplex Oligos for Illumina (New England BioLabs).Results. In 36 patients with KRAS-positive tumors, changes were observed in 13 genes involved in the molecular pathogenesis of colorectal cancer. A total of 82 somatic variants were identified. Moreover, 9 patients additionally had one mutation each, 17 patients had 2 mutations each, 7 patients had 3 mutations each, and 3 patients had 4 mutations each. Combination of three mutations in key genes involved in the pathogenesis of colorectal cancer (KRAS, APC и TP53) was detected in 15 (36 %) patients. Combination of two mutations in the KRAS and APC genes was detected in 10 (23.8 %) patients, and in the KRAS and TP53 genes – in 8 (19.1 %) patients. The largest number of somatic mutations was found in the APC (59.5 %) and TP53 (54.7 %) genes. It was hown that a combination of three mutations in key genes was the most unfavorable prognosis factor and indicated a higher aggressiveness of the tumor process.Conclusion. The information obtained using the NGS method on the mutational status of a KRAS -positive tumor in patients with colorectal cancer allows for personalized treatment as well as predicting the outcome.Keywords
This publication has 17 references indexed in Scilit:
- Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samplesJournal of Translational Medicine, 2016
- NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencingOncotarget, 2016
- Global patterns and trends in colorectal cancer incidence and mortalityGut, 2016
- Cancer prevention as part of precision medicine: ‘plenty to be done’Carcinogenesis, 2015
- Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patientsBMC Cancer, 2015
- Molecular biology of colorectal cancer in clinical practiceMolecular Biology, 2015
- Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation SequencingAmerican Journal of Clinical Pathology, 2015
- p53mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivationWorld Journal of Gastroenterology, 2015
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysisActa Oncologica, 2014
- The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinomaGut, 2005